Medical News | Hyperlipidemia

Editor's Choice

Emerging risk factors and risk markers for cardiovascular disease: Looking beyond NCEP ATP III

This review discusses emerging risk factors for CVD, including hs-CRP, lipoprotein(a), homocysteine, fibrinogen, homocysteine, and coronary artery calcification.

LATEST ARTICLES

Emerging risk factors and risk markers for cardiovascular disease: Looking beyond NCEP ATP III

This review discusses emerging risk factors for CVD, including hs-CRP, lipoprotein(a), homocysteine, fibrinogen, homocysteine, and coronary artery calcification.

Elevated CRP alone doesn't justify statin treatment

C-reactive protein (CRP) doesn't add predictive value to traditional cardiovascular risk factors, and there does not appear to be a causal association between CRP and coronary heart disease (CHD), according to results of two studies published in the July 1, 2009, issue of the Journal of the American Medical Association.

Dose of rosuvastatin daily cuts risk of major CV events

Results from the JUPITER (Justification for the use of statins in primary prevention) trial show that a daily 20 mg dose of rosuvastatin (Crestor) cut participants' risk of a major cardiac event in half, even though these were not patients current guidelines would identify as "at risk."

Rational approaches to the treatment of mixed dyslipidemia

This article reviews the role of individual therapeutic agents and combination therapies that can be used for the treatment of mixed dyslipidemia.

Statin pill-splitting has no significant effect on adherence or lipid outcomes, regardless of financial incentive

Splitting statin tablets does not negatively affect patient satisfaction, medication adherence, or lipid level control, according to the authors of a randomized, controlled study